## 1-(9-Fluorenyl)ethyl Chloroformate: A Versatile Reagent for Peptide Synthesis
1-(9-Fluorenyl)ethyl chloroformate (Fmoc-Cl) is a **key reagent in peptide synthesis**, specifically in the **solid-phase peptide synthesis (SPPS)** method. It's a crucial component because it allows for the **protection and deprotection** of amino acids during the synthesis process.
**Here's why Fmoc-Cl is important:**
* **Protection:** Fmoc-Cl reacts with the **amino group** of an amino acid, forming a **Fmoc-protected amino acid**. This protection prevents unwanted side reactions during the synthesis process.
* **Deprotection:** The Fmoc group can be selectively removed using **piperidine**, a base, under mild conditions. This allows for the addition of the next amino acid to the growing peptide chain without affecting the previously added amino acids.
* **Orthogonality:** The Fmoc protection strategy is **orthogonal** to other commonly used protecting groups in peptide synthesis, allowing for the **sequential addition of different amino acids** with different protection strategies.
* **Efficiency:** The Fmoc/piperidine system provides a **high yield and high purity** in peptide synthesis, making it a highly efficient method.
**Fmoc-Cl is widely used in research for various applications, including:**
* **Developing new therapeutic peptides:** Fmoc-Cl helps synthesize peptides with specific sequences and properties for use in drug development.
* **Studying protein structure and function:** Synthesized peptides can be used to investigate protein interactions and enzymatic activity.
* **Producing biomaterials and biocompatible polymers:** Fmoc-Cl is used to synthesize peptides for use in various materials science applications.
**Overall, Fmoc-Cl is a fundamental tool in peptide synthesis research, enabling the efficient synthesis of complex and diverse peptide molecules for various scientific applications.**
1-(9-fluorenyl)ethyl chloroformate: chiral reagent; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 115102 |
SCHEMBL ID | 1876853 |
MeSH ID | M0149797 |
Synonym |
---|
flec |
1-(9h-fluoren-9-yl)ethyl carbonochloridate |
SCHEMBL1876853 |
(+)-1-(9h-fluoren-9-yl)ethyl carbonochloridate |
1-(9-fluorenyl)ethyl chloroformate |
107474-79-3 |
carbonochloridic acid, 1-(9h-fluoren-9-yl)ethyl ester, (+)- |
(+)-1-(9-fluorenyl)ethyl chloroformate |
105764-39-4 |
154479-90-0 |
118609-65-7 |
J-001903 |
J-009108 |
DTXSID00910337 |
FT-0706990 |
FT-0738928 |
(-)-1-(9h-fluoren-9-yl)ethyl carbonochloridate |
1-(9-fluorenyl)ethylchloroformate |
STARBLD0002164 |
(-)-1-(9-fluorenyl)ethyl chloroformate solution - 18mm in acetone, for chiral derivatization |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (14.29) | 18.7374 |
1990's | 10 (47.62) | 18.2507 |
2000's | 3 (14.29) | 29.6817 |
2010's | 5 (23.81) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.88) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (13.04%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (86.96%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |